Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis.

ABSTRACT: Autoimmune hepatitis (AIH) is a rare disease of unclear etiology characterized by loss of self-tolerance that can lead to liver injury, cirrhosis, and acute liver failure. First-line treatment consists of systemic corticosteroids, or budesonide, and azathioprine, to which most patients are initially responsive, although predictors of response are lacking. Relapses are very common, correlate with histological activity despite normal serum transaminases, and increase hepatic fibrosis. Furthermore, current regimens lead to adverse effects and reduced quality of life, whereas medication titration is imprecise. Biomarkers that can predict the clinical course of disease, identify patients at elevated risk for relapse, and improve monitoring and medication dosing beyond current practice would hav

SUBMITTER: Harrington C 

PROVIDER: S-EPMC9796683 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature